Solara ActiveQ1 FY27
Solara Active Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹632P/E: 690.5Market Cap: ₹2.9K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →The company targets a sustainable revenue growth of around 10% year-on-year for the base business (Page 14-15).
- →Recent quarters show a new plateau with base business revenues crossing INR 300 crores, indicating a higher level of operations (Page 9).
- →Year-on-year growth for Q1 FY27 over Q1 FY26 was approximately 24%, and even after adjusting for pass-through cost inflation, growth was around 18-19% (Page 9).
- →Growth drivers include geographic expansion and debottlenecking capacity to increase volumes in high-margin products (Page 14).
- →Management is cautious about giving long-term (5-year) outlooks due to the dynamic external environment but expects to at least sustain or grow from the current levels (Page 14).
- →The ibuprofen business remains a commodity-driven segment with unpredictable dynamics; no specific strategic decision made yet (Pages 15-16).
Margin guidance
Category 3- →The company expects around 10% year-on-year growth in the base business revenues, considered sustainable in the near term.
- →EBITDA margins for the base business are projected to be around 25% ±1%.
- →Operating leverage is expected to contribute to profitability, but gross margin expansion and business growth will be primary drivers.
- →Gross margins are anticipated to be maintained in the 52%-55% range, depending on product mix.
- →Ibuprofen business is expected to continue posting EBITDA losses in the range of INR 10-15 crores per quarter, with strategic review ongoing.
- →Management is cautious about giving long-term (5-year) outlooks due to macroeconomic uncertainties.
- →The company targets sustainable profitable growth by focusing on expanding existing business, operational efficiency, and working capital optimization.
- →PAT has shown strong YoY growth (55% in Q1 FY27), indicating improving earnings quality.
3 more insights locked — sign up free to unlock
Fundraise plans
- →No explicit mention of any current or planned new fundraising through debt or equity in the transcript.
- →Company is focused on reducing net debt, targeting to be net debt free by FY '29.
- →Management emphasized working capital optimization and generating free cash flow to fund business needs.
- →Capital expenditure plans are focused on maintenance and debottlenecking existing facilities rather than greenfield expansion, indicating self-funded growth.
- →No clear indications of equity fundraising or major new debt issuance at this time.
- →Awaiting clarity on strategic decisions such as the ibuprofen business review by H1 FY '27, which may influence future capital allocation decisions.
Order book
YesThe provided transcript from Solara Active Pharma Sciences Limited's Q1 FY27 earnings call does not specifically mention the current or expected order book or pending orders. However, relevant insights include:
- The company is focusing on expanding its existing base business and seeding new businesses.
- The base business has shown strong momentum with revenues up 24% year-on-year.
- There is ongoing geographic expansion and new business wins.
- The company is actively manufacturing and selling around 40-50 products from a basket of 50-60 products.
- They are working on debottlenecking capacity to increase volumes for high-margin products.
- Management expresses confidence in sustaining or growing business revenue by at least 10% year-on-year.
- No quantified order book or pending orders data is explicitly provided in the transcript.
If exact order book details are needed, they may be available in a different section of the full report or through direct company disclosures.
Capex plans
Yes- →For FY '27, Solara has committed to close to INR 55-60 crores of capex.
- →Around INR 40 crores of this is towards incremental debottlenecking capex to increase capacity for high-margin products.
- →The remaining INR 10-15 crores is for maintenance capex, including plant upgrades and equipment replacements.
- →Similar capex levels of INR 40-50 crores per year are planned for FY '28 and FY '29.
- →The focus is primarily on brownfield investments—debottlenecking existing lines rather than greenfield expansions.
- →Greenfield capex is currently not being actively considered, although the company remains open to opportunities as they evolve.
- →Vizag facility retrofit plans for CRAMS work are on hold pending strategic decisions expected by Q2 FY '27 results.
- →Overall, the strategy emphasizes maximizing output via operational efficiency and capacity enhancement rather than new plant builds.
How does Solara Active rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Solara Active
Rev 3Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Solara Active rank in Pharmaceuticals & Biotechnology?
Compare Solara Active against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.